Norepinephrine augmented in vitro growth of uropathogenic E. coli in Type 2 diabetes mellitus and its suppression by silodosin (alpha blocker)

• Published in: Diagnostic microbiology and infectious disease 2018-10, Vol.92 (2), p.85-89
• Main Authors: Gond, Dinesh Prasad, Singh, Shivendra, Agrawal, N.K.
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-1 Receptor Antagonists - pharmacology; Adrenergic alpha-Agonists - adverse effects; Adrenergic alpha-Agonists - urine; Adult; Diabetes Mellitus, Type 2 - complications; Escherichia coli Infections - complications; Escherichia coli Infections - drug therapy; Escherichia coli Infections - microbiology; Humans; Indoles - pharmacology; Middle Aged; Norepinephrine; Norepinephrine - adverse effects; Norepinephrine - urine; Silodosin; Type 2 diabetes; Urinary tract infection; Urinary Tract Infections - complications; Urinary Tract Infections - drug therapy; Urinary Tract Infections - microbiology; Uropathogenic E. coli; Uropathogenic Escherichia coli - drug effects; Uropathogenic Escherichia coli - growth & development
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2018.05.005

Norepinephrine is secreted under conditions of stress in humans. The ability of bacteria to sense mammalian hormone may have a role in propagation of infection. The present study investigated the effect of norepinephrine on in vitro growth of uropathogenic E. coli (UPEC) and the effect of silodosin on norepinephrine-induced changes. The spot urine samples were collected from 56 individuals (14 diabetic patients with UTI, 14 diabetic without UTI, 14 non-diabetic UTI and 14 healthy volunteer controls) for the measurement of urinary norepinephrine concentrations. The concentration of norepinephrine, as found in urine of human subjects, was reproduced in artificial urine medium to study the growth of UPEC. The norepinephrine concentration showing maximum growth response was selected to study the effect of silodosin on the growth inhibition of UPEC. Result showed significantly elevated urinary norepinephrine in diabetic patients with and without UTI and also in nondiabetic UTI groups. The norepinephrine concentration equivalent to that in diabetic UTI patients enhanced the growth of UPEC. Furthermore, silodosin (0.32 μM) inhibited the growth of the UPEC. •In our study, urinary NE was significantly higher in type 2 diabetes.•Urinary NE excreted during stress of UTI in type 2 diabetes promotes the growth of uropathogenic E. coli.•Silodosin (α adrenergic receptor) significantly inhibits NE induced growth of uropathogenic E. coli and can be used as add-on to antibiotic therapy.